Alpha-3 beta-4 and alpha-3 beta-2 nicotinic acetylcholine receptor (α3β4 and α3β2 nAChR) (α3β4 and α3β2 nAChR)

The alpha-3 beta-4 (α3β4) and alpha-3 beta-2 (α3β2) nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that mediate fast synaptic transmission in the central and peripheral nervous systems. The α3β4 subtype is the predominant nicotinic receptor in autonomic ganglia and is also highly expressed in the medial habenula-interpeduncular nucleus pathway, where it regulates the aversive aspects of nicotine consumption and withdrawal (UniProt P32297, P30926). The α3β2 subtype, while less prevalent than the ubiquitous α4β2, contributes to neurotransmitter modulation in specific circuits. Varenicline is a high-affinity partial agonist at these receptors; its interaction with α3-containing receptors is thought to contribute to its overall efficacy and side-effect profile in smoking cessation therapy (PubChem CID 170311). By partially activating these receptors, varenicline maintains moderate levels of dopamine release to reduce cravings while blocking the reinforcing effects of inhaled nicotine. Genetic variations in the CHRNA3-CHRNB4-CHRNA5 gene cluster are strongly associated with nicotine dependence and the risk of smoking-related diseases like lung cancer (PubMed PMID: 18385676).

Other names

CHRNA3-CHRNB4 nicotinic receptorCHRNA3-CHRNB2 nicotinic receptorNeuronal acetylcholine receptor subunit alpha-3/beta-4Neuronal acetylcholine receptor subunit alpha-3/beta-2Ganglionic nicotinic receptorCHRNA3CHRNB4CHRNB2

Varenicline acts as a partial agonist at α3β4 and α3β2 nicotinic acetylcholine receptors. It binds with high affinity, stimulating a lower level of ion channel activity compared to nicotine, which helps mitigate withdrawal symptoms. Simultaneously, it acts as a competitive antagonist by preventing nicotine from binding to these same sites, thereby reducing the dopamine-mediated reward associated with smoking (StatPearls: Varenicline).